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Abstract
Treatment of chronic wounds is becoming increasingly difficult due to antibiotic resistance. Complex natural products with
antimicrobial activity, such as honey, are now under the spotlight as alternative treatments to antibiotics. Several studies
have shown honey to have broad-spectrum antibacterial activity at concentrations present in honey dressings, and
resistance to honey has not been attainable in the laboratory. However not all honeys are the same and few studies have
used honey that is well defined both in geographic and chemical terms. Here we have used a range of concentrations of
clover honey and a suite of manuka and kanuka honeys from known geographical locations, and for which the floral source
and concentration of methylglyoxal and hydrogen peroxide potential were defined, to determine their effect on growth and
cellular morphology of four bacteria: Bacillus subtilis, Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa.
While the general trend in effectiveness of growth inhibition was manuka.manuka-kanuka blend.kanuka.clover, the
honeys had varying and diverse effects on the growth and cellular morphology of each bacterium, and each organism had
a unique response profile to these honeys. P. aeruginosa showed a markedly different pattern of growth inhibition to the
other three organisms when treated with sub-inhibitory concentrations of honey, being equally sensitive to all honeys,
including clover, and the least sensitive to honey overall. While hydrogen peroxide potential contributed to the antibacterial
activity of the manuka and kanuka honeys, it was never essential for complete growth inhibition. Cell morphology analysis
also showed a varied and diverse set of responses to the honeys that included cell length changes, cell lysis, and alterations
to DNA appearance. These changes are likely to reflect the different regulatory circuits of the organisms that are activated
by the stress of honey treatment.
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Introduction
Wounds of the skin and mucosal layers can be generated by
accidental trauma, surgery, maceration, inflammation and some
cosmetic procedures (e.g. tattooing and piercing). For most
superficial wounds, healing is prompt and requires no interven-
tion. However, in some instances wounds can become infected,
and in persons with impaired immunity or circulation, wounds can
become non-healing, progressive and chronic. There is growing
evidence that chronic wounds result from a complex interplay of
host immunity and bacterial infection, and that infection can be
due to a consortia of different species of bacteria embedded in
a biofilm matrix that is highly resistant to antimicrobial therapy
[1]. Planktonic bacteria are also important in chronic and acute
wounds, and their release from biofilms has been proposed to
maintain the inflammatory response within the wound [2,3], as
well as allowing seeding to other areas. The emergence of bacterial
pathogens resistant to multiple antibiotics has exacerbated the
problems associated with treating infected wounds, particularly in
the hospital setting [4,5]. There is an increasing need for new
approaches to treat these infections, which are estimated to affect
6.5 million patients and to cost US$25 billion annually, with
significant increases expected in the future [6].
Antimicrobial honey produced from the Leptospermum scoparium
(manuka) plant from New Zealand has many features that make it
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a promising therapy for wound care. Manuka honey is broad in
spectrum and able to inhibit a diverse range of bacterial and yeast
pathogens, and is equally effective against multi-drug resistant
bacteria [7–9]. This honey has been found to prevent the
formation of biofilms and can disrupt pre-formed biofilms [10–
11]. Resistance to manuka honey has never been observed and
could not be attained under laboratory conditions that rapidly
induced resistance to conventional antibiotics [7] [9]. And finally,
honey stimulates the immune system and can promote wound
healing [12]. There are a number of medicinal honey products on
the market in the form of ointments, creams and impregnated gels.
However their use in mainstream medicine remains limited [13].
Honey has several antibacterial features that are distinct from
classical antibiotics, including high osmolarity, low pH, and the
generation of hydrogen peroxide by the bee-derived enzyme
glucose oxidase [14]. Some honeys also contain levels of bee
defensin-1 that are sufficient to inhibit growth of bacteria [15,16].
Active manuka honey contains high levels of the reactive
dicarbonyl methylglyoxal (MGO) [17,18], which forms non-
enzymatically from nectar-derived dihydroxyacetone (DHA)
during ripening. A diverse range of phenolics, complex carbohy-
drates and peptides have also been reported in honey samples, and
these may contribute to or modulate antibacterial activity [19–20].
The antibacterial activity of honey is generally assessed by
measuring the extent to which the indicator bacterium, S. aureus, is
inhibited using agar diffusion or broth micro-dilution methods
[21]. Similar tests have been performed to determine the
inhibition of other bacterial and yeast species [7] [22,23]. Manuka
honey marketed for medicinal use generally uses a potency rating
based on the ‘‘Unique Manuka Factor’’ (UMF), which measures
antibacterial activity that is unrelated to the content of hydrogen
peroxide, and is based on the S. aureus inhibition test. Alternatively,
some medicinal honeys express potency as a direct assessment of
MGO levels. While it has been established that manuka honey can
inhibit the growth of bacterial cells, its effect on growth and
cellular physiology among different bacterial pathogens, and how
these change when the levels of the major antibacterial
components, MGO and hydrogen peroxide, vary in natural
honeys are unclear. These are important considerations for
optimizing honey for wound care since sub-lethal levels of honey
may have unanticipated effects, and there is emerging evidence
that different organisms infecting a wound may respond quite
differently to the active honey components [16] [23].
To address these issues this study set out to examine the growth
response and cellular morphology of four different bacterial
species, including two of the most common wound pathogens, to
a suite of natural honey samples that differ in their levels of MGO
and hydrogen peroxide production. This included samples of
monofloral manuka honey with moderate to high MGO levels,
samples of honey produced from the New Zealand kanuka Kunzea
ericoides bush [19], where MGO levels are negligible but hydrogen
peroxide is present, and manuka-kanuka blends that contain both
active components at moderate levels. We included a set of
controls to mimic the effects of sugar, to neutralize the effect of
hydrogen peroxide, and to examine how MGO might act outside
the honey milieu. We report here that while clinically relevant
concentrations of honey are effective at inhibiting growth of all
four bacteria, the growth and morphological responses at sub-
lethal levels varied significantly between species. Furthermore, P.
aeruginosa responded strikingly differently to the other three species
(B. subtilis, E. coli and S. aureus). When present in sub-lethal
concentrations, MGO extended the lag phase of bacterial growth
in a dose-dependent manner, and the organisms eventually
resumed normal growth, presumably by detoxifying the MGO.
Topical wound dressings should therefore contain a high level of
active honey to ensure wound pathogens are eliminated.
Materials and Methods
Honey Samples
Table 1 lists the New Zealand honey samples used in this study,
which included monofloral manuka (M1, M2, M3), monofloral
kanuka (K1 and K2), manuka-kanuka blends (MK1, MK2, MK3,
MK4) and clover (C) honey. Samples were chosen based on their
levels of methylglyoxal (MGO; previously reported in Stephens
et al. 2010), and hydrogen peroxide, determined in this study.
Manuka, kanuka and manuka-kanuka honey samples were
supplied by Comvita New Zealand Ltd. (Te Puke, New Zealand)
and the clover honey sample was a commercially-packaged New
Zealand white clover honey [19]. Native New Zealand honey is
produced by bees foraging in their local environment and cannot
be guaranteed to be 100% monofloral, however the supplied
samples were considered to be as representative of pure honey
from a single floral origin as possible. Details of other chemical
components in the manuka and kanuka honeys have been
described previously [19]. All samples were stored in the dark at
4uC and were diluted fresh for use in all assays. All honey
concentrations are expressed as % w/v.
Hydrogen Peroxide Assay
The level of hydrogen peroxide produced by the honey samples
was determined using a hydrogen peroxide/peroxidase assay kit
(Amplex Red, Molecular Probes, Life Technologies Corp.,
Carlsbad, CA, USA). The assay, which measures the oxidation
by hydrogen peroxide of the non-fluorescent substrate Amplex
Red to highly fluorescent resorufin [24], was conducted in 96-well
microtitre plates according to the manufacturer’s instructions.
Resorufin fluorescence was measured at 530 nm excitation/
590 nm emission using a SpectraMax Gemini EM (Molecular
Devices, LLC, Sunnyvale, CA, USA) fluorometer. Hydrogen
peroxide standards from 5–20 mM were used to produce
a standard curve, which was then used to assess production in
duplicate samples of 2.5% and 5% w/v dilutions of the honey
samples. The results were normalized to mM H2O2/h in 1 mL of
10% w/v honey solution.
Bacterial Strains and Growth Media
Four different bacterial species were examined: the Gram-
positive bacteria B. subtilis 168 [25] and S. aureus ATCC 25923
(American Type Culture Collection), and the Gram-negative
bacteria E. coli O157:H7 [26] and P. aeruginosa PAO1 (ATCC
15692). B. subtilis is a well-studied model organism, and the other
three species are clinically relevant pathogens. Growth media were
selected to allow optimal growth of the different bacterial species:
Luria-Bertani (LB) (Oxoid Ltd., Basingstoke, Hampshire, UK)
broth and agar were used for E. coli, P. aeruginosa and B. subtilis,
while Tryptone Soya Broth and agar (Oxoid Ltd., Basingstoke,
Hampshire, UK) was used for S. aureus.
Growth of Bacterial Cultures
Planktonic bacteria in wounds, while viable, are likely to be
growing very slowly, if at all. We therefore added honey to diluted
stationary-phase bacterial cultures so that it would more accurately
represent the addition of a honey dressing to a chronic wound.
Single colonies of bacteria grown on agar were used to inoculate
broth cultures. These were grown overnight at 37uC on an orbital
shaker at 250 rpm (BiolineTM, Australia) except B. subtilis, which
was grown overnight at 30uC with slower shaking using a gyrotory
Response of Different Bacteria to Honey
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waterbath shaker (New Brunswick Scientific, Enfield, CT, USA).
The slower shaking conditions for B. subtilis ensure that this culture
does not spend too long in stationary phase, which would delay
entry into exponential growth upon dilution. Cell density of the
overnight cultures was assessed using serial-dilution plating and
was approximately 109 colony-forming units (CFU)/mL. A
suspension from the overnight culture was then diluted to a cell
density of 103 CFU/mL in fresh media containing honey to give
a final volume of 150 mL. For each growth assay, a freshly
prepared 50% (w/v) honey stock solution was made by weighing
the appropriate amount of honey and mixing this with an
equivalent amount of sterilized distilled water. This stock solution
was then further diluted with the appropriate growth medium to
give the required honey concentration. Growth of each bacterial
species was tested in six concentrations of each honey (1%, 2%,
4%, 8%, 16% and 32% w/v) in a 96-well microtitre plate format.
A microtitre plate reader (Biotek PowerWave HTH, Bioteck
Instrunents Inc, Winooski, VT, USA) programmed to measure the
optical density hourly at 595 nm (OD595nm) (Gen5H, BioTek) was
used to assay cell growth over 24 hours at 37uC, with moderate
shaking (1800 rpm, amp. 0.549 mm x-axis). Two biological
replicates, each with four technical replicates were performed for
the growth assays and each growth curve produced in Figure S1
represents the average of all data. Growth curves were presented
using GraphPad PrismV. 5.0c (Graphpad Software, San Diego,
CA, USA).
A comprehensive range of control treatments was included for
each organism in the microtitre-plate growth assays. These
included: (i) a no-treatment control; (ii) a sugar solution comprising
45% glucose, 48% fructose and 1% sucrose, (diluted as above for
honey) to identify any effects on bacterial growth due to the high
sugar content in honey; (iii) honey plus catalase (1 mg/mL) to
neutralize hydrogen peroxide [14]; (iv) a catalase-only control; (v)
MGO diluted in water to concentrations similar to those present in
honeys M1, M2 and M3 (600, 1,000 & 1,500 mg/kg undiluted
honey) at the various tested concentrations, to assess the effect of
MGO alone on bacterial growth; vi) the same MGO dilutions plus
catalase; and (vii) MGO diluted in sugar solution to the same
concentrations as above and with added catalase. MGO was
obtained as a 40% solution in water (Sigma-Aldrich Co., St Louis,
MO, USA).
Growth Curve Data Analysis
Initial inspection of the bacterial growth data indicated that the
consistent major effect of honey on growth dynamics was an
extended lag phase, such that entry into exponential growth was
delayed, and this increased with increasing honey concentrations.
Thus, we focused on how honey altered the duration of lag phase.
Lag phase was calculated as the period from inoculation to onset
of log phase, or to 10% of maximal culture absorbance. Given the
large number of different growth curves (128 individual growth
assays with 6 different honey concentrations per assay), we
automated the calculation of these parameters by fitting the
absorbance values from the bacterial growth experiments to
a generalized logistic curve (equation 1), a sigmoid function used
for growth modeling, using the Genstat program (Release 11.1
(PC/Windows) 28 January 2011, VSN International Ltd, UK).
Due to variable T values, this generalized logistic curve fitted
better than a corresponding Gompertz curve (not shown).
Y~AzC=½(1zTe{B(x{M))1=T " ð1Þ
Here, A= the lower asymptote; C= the upper asymptote;
M= time of maximum growth; B= growth rate, and T= time
near which maximum (stationary phase) growth occurs.
With these parameters, we were able to compare the effect of
the different honey samples on growth simply by plotting the
duration of lag phase (time (h)) in the presence of varying honey
concentrations (% w/v). This conversion from growth curve to lag
phase duration is illustrated in Figure S2, where a sample curve of
E. coli growth in response to a series of manuka honey M3 dilutions
(Fig. S2A, onset of log phase or 10% of maximal culture
absorbance at each honey concentration shown by ‘‘x’’) is
converted to the corresponding lag-phase honey dose response
(Fig. S2B).
Table 1. Floral source, MGO and H2O2 Levels of Honeys.




M1 2 Manukad Leptospermum scoparium var incanum 651.4 0.532
M2 13 Manuka e L. scoparium var incanum+Kunzea (?) 1004.3 0.282
M3 7 Manukae L. scoparium var incanum 1541.3 0.239
K1 22 Kanukae Kunzea ericoides 5.6 0.360
K2 21 Kanukae Kunzea ericoides 37.1 0.327
MK1 23 Manuka-Kanukae Kunzea ericoides+manuka (?) 173.6 0.583
MK2 – Manuka-Kanuka Kunzea ericoides+manuka (v. likely) 229.8 0.448
MK3 18 Manuka-Kanukae L. scoparium var ’triketone’+Kunzea 269.9 0.345
MK4 15 Manuka-Kanukad L. scoparium var ’triketone’ 307.8 0.380
C 24 Cloverf Trifollium spp. trace 0.029
aAs reported in Stephens et al. (2010).
bMGO (methylglyoxal) levels, reported in Stephens et al. (2010).
cH2O2 (hydrogen peroxide) levels are expressed as mean H2O2 production rate in 1 mL of 10% w/v honey.
dSamples collected from hive sites.
eAged samples from drums supplied by apiarists and purchased as designated type.
fObtained commercially.
doi:10.1371/journal.pone.0055898.t001
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In the vast majority of cases when growth of a culture was
detected by absorbance measurement, the maximal culture
absorbance was very similar to the no-honey control culture.
However in a few cases the maximal absorbance of the treated
culture was less than 10% of the maximal culture absorbance of
the no-honey control. In these cases, it was assessed as ‘no growth’
over the 24-hour period.
Cell Staining and Microscopy
Bacterial cultures treated with either 4% (w/v) honey M3 or
honey MK1 (Table 1) were harvested from samples obtained from
the middle of the prolonged lag phase induced by honey
treatments, and at log phase (which we will refer to as log phase)
when cultures had resumed apparently normal growth. If
a prolonged lag phase was not observed, lag phase cells were
obtained from within the first half hour of incubation. Untreated
cells from lag and log phases of growth were also harvested for
analysis, with the lag-phase cells collected 30 min after inoculation
as described above. Harvested cells were treated for microscopy as
described previously [27] but with the following modifications:
20 mL of fixed cells were diluted 1:1 with the DNA staining agent
DAPI (4’,6-diamidino-2-phenylindole; Life Technologies), to give
a final DAPI concentration of 0.4 mg/mL for E. coli, B. subtilis and
P. aeruginosa, and 0.8 mg/mL for S. aureus. Triplicate 10 mL aliquots
of the stained cells were then placed in separate wells of a multi-
well microscope slide (MP Biomedicals, LLC, Eschewege,
Germany) that had been treated with 0.01% poly-L-lysine
(Electron Microscopy Sciences, Hatfield, PA, USA). After
15 min at room temperature, the liquid was removed and 50%
glycerol was placed on each sample. A coverslip was then placed
on all samples and the edges of the coverslip were sealed with nail
polish.
Cells were imaged using phase-contrast and fluorescence
microscopy with a Zeiss Axioplan 2 fluorescence microscope
equipped with a Plan ApoChromat (100x, NA 1.4; Carl Zeiss AG,
Oberkochen, Germany) objective lens, and images were captured
using a Zeiss AxioCam MRm cooled CCD camera controlled by
AxioVision software (version 4.5; Carl Zeiss). Fluorescence
microscopy to visualize DNA stained with DAPI used a 100 W
high pressure mercury lamp passed through filter set 02 (Carl
Zeiss) as a light source. Image processing was performed using
AxioVision software version 4.5 (Carl Zeiss).
Image Data Analysis
Cell length, cell lysis and DAPI staining were assessed by digital
analysis of the captured images. Cell length and DAPI staining
were scored only for unlysed cells. A total of 152 fields of cells were
imaged and analyzed. Cell length (or diameter in the case of S.
aureus) was measured using MicrobeTracker (version 0.929) [28].
We used this MATLAB-based software to detect and outline
bacterial cells in the microscopy images and measure cell lengths
automatically. The optimized parameters (incorporated into the
MicrobeTracker software) included a modification to algorithm 4
to enable accurate cell length measurements of rod-shaped
organisms in the case of E. coli, B. subtilis and P. aeruginosa. For S.
aureus algorithm 1 was optimized to enable measurement of the
size of these spherical cells [28]. The individual cell length
information was then extracted and statistical analysis was
performed in GraphPad Prism. One-way ANOVA and Tukey’s
multiple comparison tests were performed with the no-honey
treated cells as controls. Cells that appeared lysed due to changes
in their contrast under phase-contrast microscopy were scored and
cell lysis was expressed as a percentage of the whole population.
Only cells that remained intact but appeared to lose their
cytoplasmic contents were scored, thus underestimation of cell
lysis was possible, but this was consistent across all samples. For all
experiments, at least 100 cells were scored, except for M3-treated
B. subtilis and S. aureus cells, where at least 50 cells were scored.
Results
Growth Responses to Honey, MGO, Sugar and Catalase
The growth response of two Gram-positive bacteria, B. subtilis
168 and S. aureus ATCC 25923, and two Gram-negative bacteria,
E. coli O157:H7 and P. aeruginosa PAO1 (ATCC 15692) to the 10
honeys and various control solutions were assessed. These data
comprised nearly 900 growth curves in 128 graphs (Fig. S1). For
the honey treatments each graph represents a particular honey at
six concentrations with a single organism as well as a no-honey
control, which was carried out alongside each honey sample on the
multi-well plates. A comprehensive range of control treatments
were included in the growth assays to determine the effect of
various honey components on growth of the four bacteria (see
Materials and Methods).
Time spent in lag phase before entry into exponential growth
emerged as the most notable difference among bacteria in their
response to the different honey types (see Materials and Methods).
We therefore focused our analysis on growth inhibition on this
parameter, expressed as the time taken (in hours) for the bacterial
culture to reach 10% maximal culture absorbance. The graphs
presented in Figure 1 and Figure 2 summarize the growth
responses of the four different organisms to the control solutions
(Fig. 1) and the honeys (Fig. 2). In these graphs, the time (h) taken
for a culture to enter logarithmic growth (measured as at least 10%
maximal culture absorbance; y-axis) is plotted against the honey
(or component) concentration (x-axis) for each organism both in
the absence (left panel) and presence (right panel) of catalase. Note
that the faster the rise of the line, the longer the cells are arrested
in lag phase at lower honey concentrations, and hence the more
effective a particular honey is at inhibiting the growth of that
organism. Culture growth was monitored over 24 hours, and if no
growth occurred over 24 hours, it is referred to as ‘no growth’ or
complete inhibition.
The starting absorbance values differ in each case in Figures 1
and 2 because for each honey, the no-honey control was included
to more accurately reflect the experimental conditions during that
particular experiment.
Growth Dynamics in Response to Controls: MGO and
Sugar in the Presence and Absence of Catalase
The addition of catalase to an overnight culture of bacterial cells
had essentially no effect on the duration of the lag phase, or any
other aspect of growth of the four organisms when compared with
an untreated control culture (Fig. S1). Sugar alone had a small but
variable effect on the growth of the bacteria: the Gram-positive
species B. subtilis and S. aureus were unaffected even at high
concentrations, while the two Gram-negatives became inhibited at
16–32% (Fig. 1A, 1C, 1E, 1G).
The addition of MGO at 0–32% of the concentrations present
in manuka honey samples M1, M2 and M3 (starting concentra-
tions of 600, 1,000 and 1,500 mg/kg honey) generally showed
a dose-dependent extension of lag phase (Fig 1A, 1C, 1E, 1G).
This was most severe for E. coli, followed by B. subtilis and S. aureus,
and was lowest in P. aeruginosa. The difference in sensitivity to
MGO alone between the organisms was most obvious at the lowest
MGO concentration used (blue lines in Fig. 1A, 1C, 1E, 1G).
The addition of catalase to the MGO treatments shortened the
lag-phase extension in most cases, so that the onset of log phase
Response of Different Bacteria to Honey
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Figure 1. Effect of sugar, MGO and catalase on growth of bacteria. Overnight cultures of B. subtilis, E. coli, S. aureus and P. aeruginosa were
treated with various components, including catalase, MGO, sugar, and a combination of MGO and sugar at various concentrations equivalent to
honeys at the corresponding concentrations shown on the x-axis. The MGO/sugar experiments were performed in the absence (left-hand graphs) and
presence (right-hand graphs) of catalase as indicated. The MGO levels correspond to honeys M1 (651.4 mg/kg MGO), M2 (1004.3 mg/kg MGO) and
M3 (1541.3 mg/kg MGO) at 1%–32% (w/v). Optical density was recorded at 595 nm every hour for 24 hours. For each component concentration, the
time it takes for the culture to reach log phase (assessed as at least 10% of the final culture absorbance of the untreated culture) is plotted on the x-
axis. The derivation of this value is described in Materials and Methods. A value of 24 hours on the y-axis denotes ‘no growth’. An untreated control
was performed alongside each particular treatment, and the starting OD595 (zero time-point on x-axis) is plotted for that particular honey experiment.
doi:10.1371/journal.pone.0055898.g001
Response of Different Bacteria to Honey
PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e55898
Figure 2. Effect of New Zealand manuka, kanuka and manuka-kanuka blended honeys on bacterial growth. Overnight cultures of B.
subtilis, E. coli, S. aureus and P. aeruginosa were treated with ten different honeys, plus or minus catalase: three manuka honeys, M1, M2 and M3; two
kanuka honeys, K1 and K2; four manuka-kanuka blended honeys, MK1, MK2, MK3 and MK4; and one clover honey, C, at various concentrations (from
1%–32% (w/v), increasing in 2-fold series). Optical density was recorded at 595 nm every hour for 24 hours. For each honey concentration, the time it
takes for the culture to reach log phase (assessed as at least 10% of the final culture absorbance of the untreated culture) is plotted on the x-axis. The
derivation of this value is described in Materials and Methods. A value of 24 hours on the y-axis denotes ‘no growth’. Where symbols for a particular
honey overlap, we have surrounded the point on the graph by all the symbols relevant to that point. This occurs in several cases for 16% and 32%
honey treatments. An untreated control was also performed alongside each particular honey treatment, and the starting OD595 (zero time-point on x-
axis) is plotted for that particular honey experiment.
doi:10.1371/journal.pone.0055898.g002
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occurred earlier. With the exception of P. aeruginosa, the bacteria
were still increasingly sensitive to increasing MGO concentrations
in the presence of catalase (Fig. 1, compare left with right panels).
The addition of sugar to MGO in the presence of catalase had
a small but noticeable effect on delaying the onset of log phase
further for all organisms except P. aeruginosa, particularly at the
lower sugar concentrations tested (equivalent to #8% honey;
Fig. 1).
Growth Response in the Presence of Natural Honeys
Graphs summarizing the effect of the different honey types on
growth of the four bacterial species are shown in Figure 2. From
these, four key features are particularly apparent: first, there is
a general trend of greater growth inhibition by honeys containing
more MGO, with M.MK.K.clover honey; second, the
addition of catalase causes a shift of the curves to the right for
most honey types indicating a rescue of growth inhibition; third, P.
aeruginosa has a completely different pattern of growth inhibition
compared to B. subtilis, E. coli and S. aureus; and fourth, the effect of
clover honey is different for the different bacteria. These points
will be explored further below, where the response of the bacteria
to each honey type is described.
Manuka honey. Manuka honey samples M1, M2 and M3
(Table 1) have the highest MGO concentrations of the honeys
tested, at 651.4, 1004.3 and 1541.3 mg/kg honey, respectively.
These three honeys were the most effective in inhibiting growth of
B. subtilis, E. coli and S. aureus and all resulted in similar levels of
growth inhibition. Low honey concentrations (1–4%) caused
significant lag-phase extension and growth was completely
inhibited once concentrations reached 8–16%.
In the presence of catalase the monofloral manuka honeys
remained the most effective of the natural honeys at inhibiting
growth of B. subtilis, E. coli and S. aureus, indicating that the non-
peroxide component/s in these honeys is the over-riding
component responsible for their high levels of growth inhibition.
In contrast to B. subtilis, E. coli and S. aureus, there was very little
or no lag-phase extension when P. aeruginosa was treated with low
concentrations of honeys M1–M3, and complete inhibition only
occurred at 16% of honeys M3 and M1 and 32% of honey M2. P.
aeruginosa was relatively sensitive to sugar (Fig. 1G), which likely
accounts for some of the inhibition. The addition of catalase
increased the concentration of honeys M1 and M3 required for
complete growth inhibition 2-fold (to 32%). These data and those
shown in Figure 2 indicate that P. aeruginosa is relatively insensitive
to both hydrogen peroxide and MGO, and that at 32% manuka
honey inhibition can be attributed to non-peroxide component/s.
Kanuka honey. The kanuka honeys, K1 and K2, had very
low levels of MGO (5.6 and 37.1 mg/kg, respectively), but
moderate rates of hydrogen peroxide production (0.360 and
0.327 mM/h, respectively) compared to the other honeys tested.
At low concentrations (1–8%), and particularly in the presence of
catalase, K1 and K2 were amongst the least effective of the honeys
at inhibiting growth of B. subtilis, E. coli and S. aureus, with very
little or no lag-phase extension compared to the no-honey cultures.
Complete growth inhibition with K1 and K2 occurred at 16% or
32%.
Although the addition of catalase to K1 and K2 made them less
effective at inhibiting growth of B. subtilis, E. coli and S. aureus,
complete growth inhibition still occurred at 32%; the exception
being honey K1, where lag phase was only extended by 4 hours
(Fig. 2F). The non-peroxide component causing this growth
inhibition is not likely to be due to MGO, or at least MGO acting
alone, since the amount present in 32% K1 and K2 is 11.8 and
1.8 mg/kg respectively, which is equivalent to 1% of 660 mg/kg
MGO and is therefore too low to affect growth of these bacteria
(Fig. 1A, 1C, 1E; light blue line). The inability of honey K1 to
inhibit the growth of S. aureus suggests that the component/s that
contribute to complete growth inhibition of B. subtilis and E. coli
are not active against S. aureus. Alternatively there may be
a component in honey that is specifically active against S. aureus but
requires hydrogen peroxide for its production and/or activity.
Note that S. aureus was also the only species that was not inhibited
by clover honey (see below).
P. aeruginosa growth was completely inhibited by kanuka honeys
at 16% (K1) and 32% (K2), and very little lag-phase extension was
observed. Catalase addition rescued this effect to some extent, but
at 32% the kanuka honeys completely inhibited growth of P.
aeruginosa. Again, this suggests component/s additional to MGO or
peroxide are present in these honeys that affect growth of this
organism. The most striking observation for P. aeruginosa that was
distinctly different from the other organisms was that growth was
similarly affected by kanuka honeys as by manuka honeys.
Manuka-kanuka honey blends. The responses of bacteria
to the manuka-kanuka honey blends, designated MK1–MK4, are
shown in green in Figure 2. These honeys have intermediate levels
of MGO (ranging from 173.6–307.8 mg/kg) that are between
those of the pure manuka and kanuka honeys, and variable but
significant levels of hydrogen peroxide (Table 1). Treatment with
these honeys gave a level of inhibition that was generally between
that of the pure manuka and pure kanuka honeys, especially when
the hydrogen peroxide was removed by catalase. In addition, the
degree of growth inhibition related largely to the level of MGO,
with MK4, which has the highest level of MGO of the blended
honeys (Table 1), normally being the most effective at inhibiting
growth.
While the overall pattern of growth inhibition of B. subtilis, E. coli
and S. aureus by the MK honeys was similar, there were some
notable differences in how E. coli responded to the different blends.
In the absence of catalase MK1 inhibited E. coli growth to a similar
extent as the manuka honeys, with complete growth inhibition at
8%. MK1 has a low level of MGO (173.6 mg/kg) compared to the
manuka honeys but has the highest hydrogen peroxide production
rate of all honeys. Catalase addition to MK1 reduced the level of
growth inhibition for E. coli to a level well below that of all three
manukas. These observations suggest that E. coli growth can be
maximally inhibited by honeys that either have a high level of
hydrogen peroxide production or have high levels of MGO.
P. aeruginosa displayed little or no lag-phase extension or growth
inhibition for any of the blended honeys until concentrations
reached 16% or 32%. Overall, there was no clear trend in how P.
aeruginosa responded to the varying levels of MGO and hydrogen
peroxide in the different blends, however complete growth
inhibition was achieved at 32% in the presence of catalase,
indicating that the inhibition does not require hydrogen peroxide.
Clover honey. The clover honey sample had no detectable
MGO and almost no hydrogen peroxide production (0.029 mM
H2O2/h; Table 1). Up to 16% clover honey had little effect on the
growth of the four organisms (Fig. 2). At 32%, S. aureus growth
remained unaffected, while the two Gram-negative species, E. coli
and P. aeruginosa, showed a significant lag-phase extension. This is
commensurate with the response of these two organisms to 32%
sugar (Fig. 1A, 1C, 1E and 1G). However, while the addition of
catalase to clover honey slightly increased lag phase extension, this
was not seen for the corresponding sugar control. Interestingly,
32% clover honey completely inhibited growth of B. subtilis, both
in the presence and absence of catalase even though sugar alone at
equivalent concentrations had no effect on the growth of this
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organism. This suggests the presence of one or more components
in clover honey to which B. subtilis growth is particularly sensitive.
Other observations not fitting growth inhibition
trends. Although there were clear trends in growth inhibition
in response to treatment with honeys and control solutions
discussed above, there were certain observations that did not fit
these trends that are worth acknowledging. This includes: M1,
which has the lowest level of MGO, was the most active manuka
honey for B. subtilis, E. coli and S. aureus in the presence of catalase
(Fig. 2B, 2D, 2F); the apparent abrupt (and reproducible) decrease
in growth inhibition of the MK2 honey against B. subtilis at 16% in
the presence of catalase (Fig. 2B); the incomplete inhibition of P.
aeruginosa by honey MK3 only observed when catalase was not
present (Fig. 2G); and a higher level of inhibition of E. coli by
clover honey in the presence of catalase (Fig. 2D). Given the
complexity of honey it is likely that the growth inhibition we
observe in these analyses cannot always be solely accounted for by
the presence MGO and hydrogen peroxide, and other compo-
nents may exert independent action or may modulate the response
of bacteria to MGO- and hydrogen peroxide-based toxicity.
Cellular Morphology Response in the Presence of Natural
Honeys
To determine morphological changes that occur in response to
honey containing relatively high levels of MGO or hydrogen
peroxide, B. subtilis, E. coli, S. aureus and P. aeruginosa were exposed
to honey samples M3 (highest MGO with lowest hydrogen
peroxide production of the tested honeys) and MK1 (highest rate
of hydrogen peroxide and relatively low MGO; Table 1). Cells
were treated with 4% (w/v) of each honey, which is the highest
concentration that still allowed growth of all four bacteria (see
above; Fig. 2). Cell morphology was analysed during lag- and log-
phase growth and included measures of cell shape changes (length
or width), cell lysis (breakage of cells or leakage of cytoplasm
indicating cell envelope or growth abnormalities), and detection of
chromosomal DNA abnormalities by DAPI staining.
High-level MGO honey and cell morphology. Treatment
with honey M3 induced an extended lag phase for all bacterial
cultures except P. aeruginosa (Fig. S1; Fig. 2). Morphological
changes are shown in Figure 3 and charted in Table 2, and mean
cell lengths are recorded in Table S1. During the extended lag
phase (or the initial lag phase for P. aeruginosa), cells of B. subtilis, E.
coli and S. aureus were significantly shorter (p,0.05) than untreated
cells, while P. aeruginosa cells were longer (Table 2; Fig. 3). In
addition, a significant percentage of the shorter cells of B. subtilis
(29%) and S. aureus (57%) had a condensed chromosome (green
arrows in Fig. 3). In the B. subtilis cells only one bright region of
DAPI staining occurred instead of the characteristic two regions
that represent replicating chromosomes (Fig. 3; Table 2). Likewise
the S. aureus cells with condensed chromosomes showed one or two
very small spots of DAPI-stained DNA, unlike the two larger lobes
of DNA that represent replicating chromosomes in the no-honey
control cells. No changes to DNA appearance under these
conditions were observed for E. coli or P. aeruginosa.
Following entry into log phase, cells treated with M3 honey
were still significantly different to untreated cultures (Table S1 and
Fig. 3). B. subtilis and S. aureus cells remained shorter, to a similar
degree observed in lag phase, and chromosomes remain
condensed. E. coli cells became significantly longer than their
untreated counterparts, while P. aeruginosa cells became slightly but
significantly shorter (Table 2). In addition, 2% of the P. aeruginosa
cell population now showed a condensed chromosome by DAPI
staining (green arrows in Fig. 3; Table 2).
In summary, treatment with 4% M3 honey changed mean cells
lengths of all four populations of bacteria in both lag and log
phases of growth, but the direction and the extent of change
varied. The greatest changes to cell length were observed with B.
subtilis and E. coli (Table 2). Only the Gram-positive organisms had
condensed DNA for both growth phases.
High-level hydrogen peroxide honey and cell
morphology. Treatment with 4% MK1 honey did not result
in an extended lag phase for any organism, however this honey
was particularly inhibitory to E. coli (Fig. 2). The most significant
changes to cell morphology induced by MK1 during the initial
stages of growth were observed in B. subtilis, where cells were on
average significantly shorter, as was seen with M3 but to a lesser
extent. A significant proportion of cells (34%) appeared lysed as
judged by a decrease in contrast visualized using phase-contrast
microscopy (asterisks in Fig. 3; Tables S1 and 2), and the DNA in
the vast majority of unlysed cells (90%) appeared dispersed
compared to untreated cells (Fig. 3; Table 2). No morphological
changes were observed in E. coli or P. aeruginosa cultures, and the
only change to S. aureus cells was a slight but significant decrease in
cell diameter (Table 2).
In log-phase MK1-treated B. subtilis cultures, the extent of cell
lysis was reduced from 34% in the lag-phase cultures to 2%.
However, cells were still shorter on average compared to control
cells (Table 2 and Table S1; Fig. 3), and the frequency of cells with
a dispersed DNA appearance remained very high (99%). Log-
phase S. aureus cells showed a normal morphology (Fig. 3; Table 2),
while P. aeruginosa cells were significantly shorter (Fig. 3; Table S1
and 2). Two percent of the log-phase MK1-treated P. aeruginosa
cells had the same condensed chromosome phenotype seen in the
log-phase M3-treated P. aeruginosa cells. E. coli log-phase cells
remained similar in appearance to the control cells (Table 2).
In summary, MK1 honey caused less alteration to cellular
morphology than the high-MGO honey, M3. B. subtilis cells were
the most significantly affected, with dispersed DNA, cell lysis and
cell length changes. E. coli and S. aureus had little or no apparent
change. P. aeruginosa cells were shorter in log phase only.
Correlation of Growth Inhibition and Morphological
Changes Induced by Honey
A summary of combined growth and morphology data is given
in Table 3. Overall this shows that MGO and manuka honeys are
the most effective at inhibiting growth of all organisms except P.
aeruginosa, followed by manuka-kanuka blended honeys, kanuka
honeys and then clover. P. aeruginosa is much less sensitive to the
honeys compared to the other three organisms, with little
difference in growth inhibition by the different honeys, including
clover. B. subtilis shows more morphological changes than the
other bacteria for both the high-MGO and the high-hydrogen
peroxide honeys, followed by S. aureus, P. aeruginosa and then E. coli.
Thus, with the exception of B. subtilis, where both growth and
morphology are profoundly affected by honey, the number and
severity of morphological changes do not link clearly to the level of
MGO or hydrogen peroxide in the honey, or to the effectiveness of
the honey to inhibit growth. E. coli had very little apparent
morphological changes even though its growth was affected in
a similar way to B. subtilis and S. aureus and to a much greater
extent than P. aeruginosa, with the latter conversely showing more
profound morphological changes.
Discussion
With the dearth of development of new classes of antibiotics to
treat infections caused by resistant organisms, honey is increasingly
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valued for its broad-spectrum antibacterial activity and effective-
ness as a treatment for chronic wound infections. However, as with
all natural products, there is significant chemical variation between
different honey preparations [19] and this is likely to affect the
level of antibacterial activity, and possibly, treatment outcomes. In
this study, we have therefore assessed a series of geographically-
and chemically-defined New Zealand manuka, kanuka and
manuka-kanuka blended honeys with varying concentrations of
MGO and hydrogen peroxide to determine their effectiveness in
inhibiting the growth of different species of bacteria. We show here
that, in general, the manuka honeys were the most effective at
inhibiting growth, followed by the manuka-kanuka blends and
then the kanuka honeys. However, the response of bacteria in the
presence of sub-inhibitory concentrations of these different honeys
varied with bacterial species, with each having a unique growth
and morphological response. P. aeruginosa was very different to the
other three bacteria in being both less sensitive overall and in
having a similar response to the different honey types.
Figure 3. Cellular morphology of bacterial cells treated with a high-MGO honey and a high-hydrogen peroxide honey. The effects of
4% (w/v) of a high-MGO honey (M3) and a high-hydrogen peroxide honey (MK1) on bacterial cellular morphology were examined. Overnight cultures
of B. subtilis, E. coli, S. aureus and P. aeruginosa were treated with these honeys, cells collected at both lag and log phases of growth as indicated in
Figure S2, fixed with glutaraldehyde, stained with DAPI and imaged using fluorescence microscopy. All images are overlays of the phase-contrast
image and the DAPI-stained (red) fluorescence image. The two left-hand panels show the no-honey treated control cells, the two middle panels M3
honey-treated cells, and the two right-hand panels show the MK1 honey-treated cells. In all images, condensed DNA is shown by green arrows; and
dispersed DNA in B. subtilis cells is shown by blue arrows. An asterisk indicates lysed cells for B. subitlis (MK1, lag-phase cells). The scale bar represents
2 mm, except for S. aureus images, where it represents 1 mm.
doi:10.1371/journal.pone.0055898.g003
Table 2. Cell morphology changes with high-MGO honey and high-hydrogen peroxide honey treatmenta.
B. subtilis E. coli S. aureus P. aeruginosa
Length Lysis DNA Length Lysis DNA Length Lysis DNA Length Lysis DNA
M3 lag Q (1.8x) – Condensed (29%) Q (1.8x) – – Q (1.2x) – Condensed (57%) q (1.1x) – –
M3 log Q (1.4x) – Condensed (23%) q (1.6x) – – Q (1.2x) – Condensed (57%) Q (1.1x) – Condensed (2%)
MK1 lag Q (1.2x) 34% Dispersed (90%) – – – Q (1.1x) – – – – –
MK1 log Q (1.2x) 2% Dispersed (99%) – – – – – – Q (1.6x) – Condensed (2%)
aActual mean cell lengths and statistics are shown in Table S1.
QStatistically significant decrease compared to no-honey treated cells (p,0.05).
qStatistically significant increase compared to no-honey treated cells (p,0.05).
–No change.
doi:10.1371/journal.pone.0055898.t002
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High-throughput Analysis of Growth Dynamics Reveals
that MGO in Honey Extends the Duration of Lag Phase
A high-throughput approach was used to assess the growth and
morphological effects of a large number of natural honeys on
multiple organisms. This approach is novel in honey studies and
was employed here to address the challenge of assessing multiple
parameters in a complex natural product. This system allowed us
to explore the heterogeneous and variable composition of natural
honey by analyzing large numbers of samples and control
solutions, and showed the dynamic response of cell growth in
response to the effects of honey toxicity. Such an approach may be
useful in the study of other natural products where activity is
modulated by various interacting factors.
Visual inspection of the resulting large number of growth curves
revealed a distinctive dose-dependent extension of lag phase of
growth when cultures of B. subtilis, E. coli and S. aureus were treated
with manuka honey. This growth behavior was also observed
when MGO alone was added to these bacterial cultures (Fig. 1),
and is consistent with a previous study where E. coli was subjected
to MGO treatment [29]. Lag-phase extension was not seen for
clover or pure kanuka honeys; in these growth was either
unaffected or was completely inhibited, and there was no evidence
for dose-dependent recovery over time (Fig. S1). Thus the
extended duration of lag phase is presumed to be largely or
completely due to MGO and is likely to be unique to honey
derived from manuka and other Leptospermum species.
Growth and Morphology of Different Bacteria are
Affected by Honey in Markedly Different Ways
The dynamics of growth in the presence of the different honey
types was relatively similar for B. subtilis, E. coli and S. aureus but
differed markedly in P. aeruginosa (Figs. 1 and 2). The extended
duration of lag phase and the eventual resumption of logarithmic
growth in the presence of MGO likely reflect induction of the
glyoxylase system used to detoxify MGO [30]. All organisms
produce MGO, which appears to be important in allowing them
to regulate growth and maintain carbon flux as their environment
changes [31–32]. However, as MGO is toxic, cells detoxify this
compound to D-lactate using two metalloenzymes, GlxI and GlxII
(Cooper, 1984). The ability of P. aeruginosa to grow in the presence
of higher MGO levels than the other bacteria may reflect more
efficient detoxification of MGO; a suggestion supported by the
discovery, through genome sequencing, that P. aeruginosa is unique
among eubacteria in its possession of three (rather than one) fully
functional GlxI homologs [33].
To date, few microscopy studies have been performed to
identify morphological changes to bacterial cells treated with
honey, and none have used high-throughput phase-contrast and
fluorescence microscopy that allows a large number of cells to be
imaged and measured rapidly. We observed bacterial cell length
changes in all organisms treated with manuka (high-MGO) honey.
This is caused by an adjustment to the frequency of cell division
relative to growth rate, often due to a change in nutritional state,
such that division occurs at a different cell length to untreated cells
[34]. Condensed DNA was also observed in a significant pro-
portion of B. subtilis and S. aureus cells treated specifically with
manuka honey. This could be a consequence of inhibition of
initiation of DNA replication [35,36]; a suggestion consistent with
previous studies demonstrating that MGO alone inhibits this phase
of DNA replication in bacterial cells [37]. Treatment with honey
that contained the highest level of hydrogen peroxide (MK1)
caused significant changes to the morphology of B. subtilis cells,
including a dispersed appearance of the DNA. This could reflect
a degree of DNA degradation due to hydrogen peroxide in the
honey causing oxidative DNA damage [38].
With the exception of B. subtilis, the number and severity of
morphological changes do not link clearly to the level of MGO or
hydrogen peroxide in the honey, or to the effectiveness of the
honey to inhibit growth. This is not entirely unexpected since cell
morphology often reflects a response to changes in the environ-
ment that allows the organism to adapt to that environment
without having to change its rate of growth. Different organisms
do this differently when faced with a variety of nutritional and
environmental conditions, such as oxidative or nutrient stress. This
might reflect, at least in part, the degree of variation of the
environment that these organisms inhabit [39]. We therefore
speculate that the differences in morphology that we observe in
response to a particular honey reflect species-specific differences in
the regulatory circuits that coordinate growth with cellular
physiology.
MGO and Hydrogen Peroxide Production cannot
Account for All Activity Present in Manuka, Kanuka and
Clover Honey
Commensurate with previous studies [8,15,40,41], we found
that even when the peroxide activity was neutralized with catalase
and there were negligible levels of MGO present, honey could
inhibit bacterial growth. Even clover honey, with only trace levels
of MGO and hydrogen peroxide, had variable effects on the four
bacteria that in most cases could not be attributed to sugar alone.
Table 3. Summary of growth and morphological effects of honeys and control treatments on all organisms.
Growth Inhibition Cell Morphologya
Organism MGO Sugar Clover M K MK High-MGO Honey (M3) High-H2O2 Honey (MK1)
B. subtilis XXXb –c X XXXX XX XXX Shorter cells; condensed DNA
(25%)
Shorter cells; lysis; dispersed DNA
(95%)
E. coli XXXX XX X XXXX XX XX Shorter and longer cells –
S. aureus XXX – – XXXX XX XX Shorter cells; condensed DNA
(57%)
Shorter cells
P. aeruginosa XX X X XX XX XX Shorter and longer cells;
condensed DNA (2%)
Shorter cells; condensed DNA (2%)
athis data includes data from both the log and lag phases of growth.
bThe number of crosses increases the more growth is inhibited.
cMeans no effect.
doi:10.1371/journal.pone.0055898.t003
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These observations are in line with previous studies suggesting that
the presence of additional antibacterial components that may be
directly active or may modulate the activity of the dominant active
components [8,40,41]. These additional components may include:
(i) phenolics derived from the floral source [19]; (ii) bee-derived
antimicrobial peptides (although note that bee defensin-1, an
antibacterial component of Revamil honey [8], could not be
identified in manuka or kanuka honeys) [23] [42]; and (iii) as yet
undefined synergistic compounds identified in other studies,
including transition metals [38,43,44].
Clinical Applications of Antibacterial Honey
The range of effects induced by the different honeys in the
bacterial species tested reflects a diversity of responses that could
be expected by bacteria present in chronic wounds. Our findings
here have important implications for the clinical application of
honey in the treatment of these wounds. First, sub-inhibitory
concentrations of MGO may be neutralized by bacteria which
then resume normal growth, thus any honey formulation should
contain sufficient active honey to sustain inhibition. Second, honey
without significant levels of MGO or hydrogen peroxide, such as
clover honey, may be able to inhibit some bacteria but is not
broad-spectrum and is therefore not recommended for infected
wounds where multiple species may be present. Third, MGO at
600 mg/kg honey achieves almost as much inhibition as much
higher concentrations, and increasing MGO above this threshold
may not result in a more effective honey. And finally, in honey
containing both MGO and hydrogen peroxide, MGO provides an
over-riding activity and if this level is high enough, hydrogen
peroxide does little to augment activity.
To date, more than 80 different microbial species, including
bacteria and yeast pathogens known to infect wounds, have been
shown to be inhibited by honey [22,45,46]. In the current study,
the use of sub-inhibitory concentrations of honey has enabled us to
examine the nature of honey inhibition, however these concentra-
tions are well below those that would be used in a clinical situation,
where whole honey is generally applied and complete and
irreversible inhibition would be expected.
Emerging evidence from clinical studies suggests that honey is at
least as effective as conventional treatments in healing wounds,
particularly in very refractory cases such as in diabetics, the
elderly, and extensively burned patients [47,48], but more clinical
data are necessary for robust statistical appraisal [49]. Here, we
have demonstrated the potency of natural honey as an antimicro-
bial wound dressing, and that multiple effects arise from a variety
of active compounds, which not only allows active honey to be
uniquely broad in spectrum, but also reduces the potential for
resistant microbial populations to evolve. Use of the full honey
matrix is therefore recommended for the treatment of infected
wounds. Understanding the complex nature of honeys and its
effects on bacterial pathogens may eventually allow the de-
velopment of specific blends with an optimal combination of
antibacterial components, thus ensuring a highly effective and
resilient antibacterial wound treatment option.
Supporting Information
Figure S1 The effect of New Zealand honey treatments
on bacterial growth. Growth curves of B. subtilis (001–032), E.
coli (033–064), S. aureus (065–096) and P. aeruginosa (097–128) were
treated with 10 different honeys (three manuka honeys, M1, M2,
M3; four manuka/kanuka blended honeys, MK1, MK2, MK3,
MK4; two kanuka honeys, K1, K2; and a clover honey, C) and
a comprehensive range of controls, which included (i) a sugar
solution comprising 45% of glucose, 48% of fructose and 1% of
sucrose; (ii) honey plus catalase (1 mg/mL); (iii) a catalase-only
control; (iv) three MGO solutions at starting concentrations
matching that present in undiluted honeys M1, M2 and M3 (600,
1,000 & 1,500 mg/kg) and diluted the same as honey; v) a range of
MGO concentrations plus catalase; and finally (vi) different MGO
concentrations in the presence of both catalase and sugar solution
at various concentrations (0% - as no honey control, 1%, 2%, 4%,
8%, 16% & 32% (w/v), represented by dark blue, light blue,
green, pink, orange, purple and red color respectively). Optical
density was recorded at 595 nm every h for 24 h. The optical
density was then log-transformed and plotted against time using
GraphPad Prism 5.0.
(PDF)
Figure S2 Transformation of data obtained for bacteri-
al growth with honey treatment. Panel A illustrates the effect
of various (1–32% (w/v)) concentrations of honey M3 on E. coli
growth over 24 h as a simple log OD595nm versus incubation time.
The point at which 10% of the final OD595nm is reached is shown
by an ‘x’ on each growth curve. Panel B summarizes all the data
from panel A as a simple relationship between honey concentra-
tion and the time it takes to reach 10% of the total OD595nm. A
value of 24 hours on the y-axis denotes ‘no growth’.
(TIF)
Table S1 Average cell length after different honey
treatment (mm). Cell lengths were not significantly affected by
the honey treatments (p.0.05); all other values are significantly
different (p,0.05); n $50. M3–4% manuka M3 (high-MGO)
honey treatment. MK1–4% manuka-kanuka blended (high-
hydrogen peroxide) honey treatment.
(DOCX)
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journal published by the Public Library of Science
(initially PLoS, since 2012 PLOS) since 2006. It covers
primary research from any discipline within science and
medicine. All submissions go through an internal and
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PLOS ONE was launched in December 2006 as a beta
version named PLoS ONE. It launched with Commenting
and Note making functionality, and added the ability to
rate articles in July 2007. In September 2007 the ability
to leave "trackbacks"[1] on articles was added. In August
2008 it moved from a weekly publication schedule to a
daily one, publishing articles as soon as they became
ready.[2] In October 2008 PLOS ONE came out of
"beta". Also in September 2009, as part of its
"Article-Level Metrics" program, PLOS ONE made the
full online usage data for every published article (HTML
page views, PDF, and XML downloads) publicly
available. As part of a rebranding of PLoS as PLOS, the
journal changed its name to PLOS ONE in mid-2012.[3]
PLOS ONE - Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/PLoS_ONE
1 of 6 10/08/2012 4:45 PM
A birthday cake celebrating five years





In 2006, the journal published 138 articles; in 2007, it published just
over 1,200 articles; and in 2008, it published almost 2,800 articles,
making it the largest open access journal in the world. In 2009, 4,406
articles were published, making PLOS ONE the third largest
scientific journal in the world (by volume) and in 2010, 6,749 articles
were published, making the journal the largest in the world (by
volume).[4] In 2011, the journal published 13,798 articles,[5] meaning
that approximately 1 in 60 of all articles indexed by PubMed as being
published in 2011 were published by PLoS ONE [6]
Management
The founding managing editor was Chris Surridge.[7] He was succeeded by Peter Binfield in March 2008,
who was publisher until May, 2012. The current executive editor is Damian Pattinson.[8]
Publication concept
PLOS ONE is built on several conceptually different ideas compared to traditional peer-reviewed scientific
publishing in that it does not use the perceived importance of a paper as a criterion for acceptance or
rejection. The idea is that, instead, PLOS ONE only verifies whether experiments and data analysis were
conducted rigorously, and leaves it to the scientific community to ascertain importance, post publication,
through debate and comment.[9] This, however, is not always achieved in practice since editors and
reviewers might have a subjective opinion about the articles they are reviewing which in turn might lead to
the acceptance or rejection of papers of doubtful quality or intent.
“ Each submission will be assessed by a member of the PLOS ONE Editorial Board beforepublication. This pre-publication peer review will concentrate on technical rather thansubjective concerns and may involve discussion with other members of the Editorial Board
and/or the solicitation of formal reports from independent referees. If published, papers will
be made available for community-based open peer review involving online annotation,
discussion, and rating.[10] ”
According to Nature, the journal's aim is to "challenge academia's obsession with journal status and impact
factors."[11] Being an online-only publication allows PLOS ONE to publish more papers than a print journal.
It does not restrict itself to a specific scientific area in an effort to facilitate publication of research on topics
outside, or between, traditional science categories.[9]
Papers published in PLOS ONE can be of any length, contain full color throughout, and contain
supplementary materials (such as multimedia files). Reuse of articles is subject to a Creative Commons
Attribution License, version 2.5. The journal uses an editorial board of almost 2,600 academics and in the
first four years following launch it made use of over 35,000 external peer reviewers.[12] PLOS ONE
publishes approximately 70 % of all submissions, after review by, on average, 2.8 experts.[13]
Business model
As with all journals of the Public Library of Science, PLoS ONE is financed
by charging authors a publication fee. The "author-pays" model allows
PLoS journals to provide all articles to everybody for free (open access)
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A welcome message from
PLoS to Nature Publishing
Group on the launch of
Scientific Reports,[14] inspired
by a similar message sent in
1981 by Apple to IBM upon the
latter's entry into the personal
computer market with its IBM
Personal Computer.[15]
immediately after publication. As of July 2010, PLoS ONE charges authors
$1,350[16] to publish an article. It will waive the fee for authors who do not
have sufficient funds.[17] This model has drawn criticism, however. Richard
Poynder argues that journals such as PLoS ONE that charge authors for
publication rather than charging users for access may produce a conflict of
interest that reduces peer review standards (accept more articles, earn more
revenue).[18] Stevan Harnad instead argues for a "no fault" peer review
model, in which authors are charged for each round of peer review,
regardless of the outcome, rather than for publication.[19]
PLoS had been operating at a loss until 2009 but covered its operational
costs for the first time in 2010,[20] largely due to the growth of PLoS ONE. The PLoS ONE model has
inspired a series of journals with a broad scope that are published under Creative Commons licenses, e.g.
Scientific Reports (published by Nature Publishing Group)[21][22][23] and Open Biology (published by the
Royal Society).[24]
Community recognition and citation information
In September 2009, PLoS ONE received the Publishing Innovation Award of the Association for Learned
and Professional Society Publishers.[25] The award is given in recognition of a "truly innovative approach to
any aspect of publication as adjudged from originality and innovative qualities, together with utility, benefit
to the community and long term prospects". In January 2010 it was announced that it was to be analyzed by
Journal Citation Reports.[26] Its 2011 impact factor is 4.092.[27] Additionally, the Scopus Journal Analyzer
reports a "trend line" (total citations to all articles ever published received in a year divided by total number
of articles published in that year) value of 3.74 for PLoS ONE for the year 2009 (up to February 10,
2010).[28]
A number of Nobel Laureates have published studies in PLoS ONE, including Françoise Barré-Sinoussi,[29]
Elizabeth H. Blackburn,[30] Jack W. Szostak,[31] Oliver Smithies,[32] and Barry Marshall.[33]
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